Document Detail


Parenteral insulin suppresses T cell proliferation to islet antigens.
MedLine Citation:
PMID:  20522167     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The diabetes prevention trial-type 1 (DPT-1) tested whether a combination of SQ and IV insulin therapy would delay the onset of disease in individuals at high risk of progression. We investigated whether this regimen altered T cell responses to human islet proteins using cellular immunoblotting. Among the 10 treated and 7 control subjects studied, we found that there was a significant effect of treatment on cellular immunoblotting responses. We conclude that parenteral insulin may suppress proliferation to islet antigens in individuals at risk for diabetes, but this effect may be transient. Further study is needed to determine whether a therapy that results in sustained suppression of T cell proliferation could yield a measurable clinical benefit.
Authors:
Carla J Greenbaum; Marli McCulloch-Olson; Harvey K Chiu; Jerry P Palmer; Barbara Brooks-Worrell
Related Documents :
219567 - Encephalomyocarditis virus-induced diabetes mellitus treated by islet transplantation.
19333547 - Binding of sars coronavirus to its receptor damages islets and causes acute diabetes.
3024737 - Production of inositol trisphosphates and inositol tetrakisphosphate in stimulated panc...
7646447 - The stimulation of insulin secretion by d-glyceraldehyde correlates with its rate of ox...
8636267 - Insulin resistance in growth hormone-deficient adults: defects in glucose utilization a...
12472377 - Protein tyrosine phosphatases as drug targets: ptp1b and beyond.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Pediatric diabetes     Volume:  12     ISSN:  1399-5448     ISO Abbreviation:  Pediatr Diabetes     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-26     Completed Date:  2011-08-18     Revised Date:  2012-05-02    
Medline Journal Info:
Nlm Unique ID:  100939345     Medline TA:  Pediatr Diabetes     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  150-5     Citation Subset:  IM    
Copyright Information:
© 2010 John Wiley & Sons A/S.
Affiliation:
Benaroya Research Institute, Seattle, WA, USA. cjgreen@benaroyaresearch.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Autoantibodies / blood,  immunology
Cell Division / drug effects,  immunology
Child
Diabetes Mellitus, Type 1 / drug therapy*,  epidemiology,  prevention & control*
Disease Progression
Humans
Hypoglycemic Agents / administration & dosage*,  immunology
Injections, Intravenous
Injections, Subcutaneous
Insulin / administration & dosage*,  immunology
Islets of Langerhans / immunology
Parents
Risk Factors
T-Lymphocytes / cytology,  drug effects*,  immunology
Young Adult
Grant Support
ID/Acronym/Agency:
M01-RR-00037/RR/NCRR NIH HHS; P30 DK017047-33S3/DK/NIDDK NIH HHS; P30 DK17047/DK/NIDDK NIH HHS; U01 DK046601-07/DK/NIDDK NIH HHS; U01 DK46601/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Hypoglycemic Agents; 0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evolution of development of vascular cambia and secondary growth.
Next Document:  Glycemic control and type 1 diabetes: the differential impact of model of care and income.